Tau PET Imaging in People With Mild Alzheimer Disease Receiving Amyloid Therapy
Uses brain scans with tracers to study tau in people with mild Alzheimer disease.
Plain-language title generated from the registry record
Registry title: Tau PET Outcomes With Anti-amyloid Immunotherapies
Key facts
- Where
- Rochester, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 90 years old?
Source: NCT06723015, who can take part
Where in United States
- Mayo ClinicRochester, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT06723015
- Record updated
- 30 October 2026
- Original description
This is an imaging study of patients with mild Alzheimer's disease receiving amyloid-targeting therapy and under the care of neurologists at Mayo Clinic in Rochester, MN.Read full original descriptionShow less
Study of Tau PET Outcomes in Patients Receiving Anti-amyloid Immunotherapies
This is an imaging study of patients with mild Alzheimer's disease receiving amyloid-targeting therapy and under the care of neurologists at Mayo Clinic in Rochester, MN.
Inclusion: Age 50-90 years; Male or female; Mild cognitive impairment due to AD or mild AD; Amyloid positive via CSF or PET; Meets other eligibility criteria for anti-amyloid immunotherapy; Subject or delegate provides informed consent.
Exclusion: Subjects unable to lie down without moving for 10 minutes; Women who are pregnant or cannot stop breast feeding for 24 hours; Claustrophobic patients unable to tolerate the scans (no sedation can be offered).